3 completed, 1 terminated. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow tariquidar: new trials by email Literature Review of tariquidar trials Research Report on tariquidar
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tariquidar-ondansetron Combination in Neuropathic Pain Ondansetron 16 mg with Tariquidar, Ondansetron 16 mg with Placebo - Neuropathic Pain | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 24 | 2021-01-31 | 2025-08-14 |
| Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers Ondansetron 8mg with Saline & Tariquidar, Ondansetron 16mg with Saline & Tariquidar - Neuropathic Pain | Phase 1 | Terminated | Washington University School of Medicine | 14 | 2019-05-20 | 2022-04-07 |
| Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors Tariquidar - Wilms' Tumor, Sarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2001-02-15 | 2019-07-16 |
| Vinorelbine and XR9576 to Treat Cancer Vinorelbine, XR9576 - Breast Cancer, Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 1999-12-01 | 2008-03-04 |
Neoplasms (2) · Neuralgia (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Lung Neoplasms (1) · Ovarian Neoplasms (1) · Sarcoma (1) · Wilms Tumor (1)
National Cancer Institute (NCI) (2) · Washington University School of Medicine (2)
United States (4)
Simon Haroutounian, PhD (2) · Brigitte C Widemann, M.D. (1)